Oligonucleotide compositions with enhanced efficiency

Patent metadata

Field	Value
Publication number	US-10626398-B2
Application number	US-201916253180-A
Country	US
Kind code	B2
Filing date	Jan 21, 2019
Priority date	Feb 1, 2002
Publication date	Apr 21, 2020
Grant date	Apr 21, 2020

Abstract

The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.

First claim

The invention claimed is:

1. A composition comprising a combination of double-stranded oligonucleotides, the combination consisting of three or more different double-stranded oligonucleotides in equimolar concentrations,
wherein each double-stranded oligonucleotide is targeted to a different sequence within a single target gene,
each double-stranded oligonucleotide consists of two separate strands,
each strand is between 15 and 40 nucleomonomers in length;
wherein the combination is capable of RNA interference (RNAi).

2. The composition of claim 1 wherein each strand is between 20 and 30 nucleomonomers in length.

3. The composition of claim 1 wherein at least one of the oligonucleotides comprises at least one modified sugar moiety or at least one modified internucleoside linkage.

4. The composition of claim 1 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

5. The composition of claim 1 wherein at least one of the double-stranded oligonucleotides is covalently linked to an agent to facilitate cellular uptake.

6. The composition of claim 1 , wherein the target gene is a mammalian gene.

7. A composition comprising a combination of double-stranded oligonucleotides, the combination consisting of two different double-stranded oligonucleotides in equimolar concentrations,
wherein each double-stranded oligonucleotide is targeted to a different sequence within a single target gene,
each double-stranded oligonucleotide consists of two separate strands,
each strand is between 15 and 40 nucleomonomers in length,
wherein the combination is capable of RNA interference (RNAi).

8. The composition of claim 7 wherein each strand is between 20 and 30 nucleomonomers in length.

9. The composition of claim 7 wherein at least one of the oligonucleotides comprises at least one modified sugar moiety or at least one modified internucleoside linkage.

10. The composition of claim 7 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

11. The composition of claim 7 wherein at least one of the double-stranded oligonucleotides is covalently linked to an agent to facilitate cellular uptake.

12. The composition of claim 7 , wherein the target gene is a mammalian gene.

13. A composition comprising a combination of double-stranded oligonucleotides, the combination consisting of three, four, five, six, seven or eight different double-stranded oligonucleotides in equimolar concentration,
wherein each double-stranded oligonucleotide is targeted to a different sequence within a single target gene,
each double-stranded oligonucleotide consists of two separate strands,
each strand is between 15 and 40 nucleomonomers in length,
wherein the combination is capable of RNA interference (RNAi).

14. The composition of claim 13 wherein each strand is between 20 and 30 nucleomonomers in length.

15. The composition of claim 13 wherein at least one of the oligonucleotides comprises at least one modified sugar moiety or at least one modified internucleoside linkage.

16. The composition of claim 13 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

17. The composition of claim 13 wherein at least one of the double-stranded oligonucleotides is covalently linked to an agent to facilitate cellular uptake.

18. The composition of claim 13 wherein the combination of double-stranded oligonucleotides consists of three or four different double-stranded oligonucleotides in equimolar concentration.

19. The composition of claim 18 wherein the combination of double-stranded oligonucleotides consists of four different double-stranded oligonucleotides in equimolar concentration.

20. A method of inhibiting protein synthesis in a cell comprising
contacting the cell with the composition of claim 1 thereby inhibiting the synthesis of a target protein.

21. A method of inhibiting protein synthesis in a cell comprising
contacting the cell with the composition of claim 7 thereby inhibiting the synthesis of a target protein.

22. A method of inhibiting protein synthesis in a cell comprising
contacting the cell with the composition of claim 13 thereby inhibiting the synthesis of a target protein.

Assignees

• Life Technologies Corp

Inventors

• Woolf Tod
• Taylor Margaret

Classifications

• C12N2310/111

  spanning the whole gene, or a large part of it · CPC title

• C12N2310/11

  Antisense · CPC title

• C12N2310/315

  Phosphorothioates · CPC title

• A61P31/12

  Antivirals · CPC title

• C12N15/1137 Primary

  against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title